OmniActive explains in a press release that Chopra has a wealth of experience in general management, commercial, manufacturing, mergers & acquisitions, and innovation, most recently serving as managing director for India and South Asia at Thermo Fisher Scientific.
OmniActive Health Technologies (Bridgewater, NJ and Mumbai, India) has announced the appointment of Amit Chopra as the company’s new president and chief executive officer. OmniActive explains in a press release that Chopra has a wealth of experience in general management, commercial, manufacturing, mergers & acquisitions, and innovation, most recently serving as managing director for India and South Asia at Thermo Fisher Scientific. Prior to this, he held a number of leadership positions with ICI in India and Asia Pacific. Chopra holds a bachelor’s degree in chemistry from St. Stephen’s College, University of Delhi, and an MBA in marketing and finance from XLRI Jamshedpur, India.
“OmniActive has continued to experience tremendous growth in recent years, and as we examined our ambitious goals, it was clear that we needed a leader to drive expansion in key global regions while overseeing our operations in India,” said Sanjay Mariwala, founder and executive chairman of OmniActive, in a press release. “I am confident that Amit’s strategic thinking, business acumen, and successful record of execution will be invaluable in shaping the Company’s future.”
“OmniActive is a pioneer and an innovator, and the company’s investments in research and sustainability have led to meaningful breakthroughs in the global healthcare and nutraceuticals industries,” said Chopra. “OmniActive’s inspiring mission of ‘improving lives through innovative science and natural health solutions’ aligns closely with my values. I am thrilled to join OmniActive as president and CEO and look forward to working with OmniActive’s talented team to accelerate business growth."
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.